Investor Presentaiton

10 Differentiated Innovation - from R&D to Market Rituximab Injection Trastuzumab Injection Serplulimab Injection FCN-338 (BCL-2) • FCN-159 (MEK) • ORIN-1001 In-house R&D Azvudine Avatrombopag Tablets • Opicapone • RT002 • Tenapanor Tablets • SurVaxM FS-1502 • Gene Therapy 马来酸阿伏曲油帕片 Doprelet mRNA Covid-19 Vaccine Axicabtagene Ciloleucel In-license • da Vinci Surgical System BIONTECH Kite INTUITIVE • AGILEAD SURGICAL Co-development Diversified R&D System Oncolytic Virus Individualized Vaccine for Cancer Treatment(AC- NP)/Multispecific Immunonano Therapy(MINP) Lung Cancer Early Diagnosis and treatment (Jedicare) Strengthen middle office capabilities including project approval, clinical, registration, etc. Commercialization team with over 6,900 employees to maximize product value Incubation & Early Stage Investments

View entire presentation